AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference
June 02 2022 - 4:05PM
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology
company developing first-in-class antibodies focused on emerging
immune control mechanisms applicable to inflammation and
immuno-oncology indications, today announced that Dan Faga, chief
executive officer, and Paul Lizzul, chief medical officer of
AnaptysBio, will represent the company in a fireside chat at the
Jefferies Healthcare Conference on Wednesday, June 8, 2022, at
10:00 a.m. ET / 7:00 a.m. PT.
A live audio webcast of the presentation will be available on
the investor section of the AnaptysBio website at
https://ir.anaptysbio.com/events. A replay of the
webcast will be available for 90 days following the event.
About AnaptysBio
AnaptysBio is a clinical-stage biotechnology company
developing first-in-class antibodies focused on emerging immune
control mechanisms applicable to inflammation and immuno-oncology
indications. The Company’s proprietary anti-inflammatory pipeline
includes imsidolimab, its anti-IL-36R antibody, previously referred
to as ANB019, for the treatment of dermatological inflammatory
diseases, including generalized pustular psoriasis, or GPP, and
moderate-to-severe hidradenitis suppurativa; rosnilimab, its
anti-PD-1 agonist program, previously referred to as ANB030, for
the treatment of moderate-to-severe alopecia areata; and its
anti-BTLA agonist program, ANB032, which is broadly applicable to
human inflammatory diseases associated with lymphoid and myeloid
immune cell dysregulation. AnaptysBio’s antibody pipeline has been
developed using its proprietary somatic hypermutation, or SHM
platform, which uses in vitro SHM for antibody discovery
and is designed to replicate key features of the human immune
system to overcome the limitations of competing antibody discovery
technologies. AnaptysBio has also developed multiple
therapeutic antibodies in an immuno-oncology collaboration with
GSK, including an anti-PD-1 antagonist antibody (JEMPERLI
(dostarlimab-gxly) GSK4057190), an anti-TIM-3 antagonist antibody
(cobolimab, GSK4069889) and an anti-LAG-3 antagonist antibody
(GSK4074386).
Contact:Dennis MulroyAnaptysBio,
Inc.858.732.0201dmulroy@anaptysbio.com
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Jun 2024 to Jul 2024
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Jul 2023 to Jul 2024